Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.2% Today

What is Novo Nordisk A/S?

Novo Nordisk (NVO) specializes in diabetes care and obesity management drugs. The market saw significant downward movement for NVO today.

Why is Novo Nordisk A/S going down?

NVO stock is down 5.2% on Nov 6, 2025 20:42

• Disappointing Q3 earnings and revenues for Novo Nordisk were driven by the slower growth of its obesity drugs, Wegovy and Ozempic, particularly in the U.S.
• Despite efforts to reduce drug prices and improve patient access, challenges in the pharmaceutical industry may have led to a negative market response.
• Competition, exemplified by Pfizer's unsuccessful attempt to block Novo Nordisk's acquisition of Metsera, likely impacted Novo Nordisk's stock price.
• Novo Nordisk revising its growth forecast for obesity drugs may have raised concerns about future profitability and market performance.

NVO Price Chart

NVO Technical Analysis

NVO News

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide ...

https://www.globenewswire.com/news-release/2025/11/06/3182956/0/en/Novo-Nordisk-announces-agreement-with-the-U-S-Administration-to-bring-GLP-1s-to-more-Americans-at-a-lower-cost.html

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits - Novo Nordisk ( NYSE:NVO )

At the ObesityWeek, Novo Nordisk A/S ( NYSE:NVO ) presented new findings from the STEP UP phase 3b trial. The Novo Nordisk STEP UP phase 3b trial investigated the efficacy and safety of a higher, 7.2 mg dose of semaglutide compared to the 2.4 mg dose and a placebo for weight management in ...

https://www.benzinga.com/news/health-care/25/11/48694189/higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal - Metsera ( NASDAQ:MTSR ) , Novo Nordisk ( NYSE:NVO ) , Pfizer ( NYSE:PFE )

The Delaware Chancery Court denied Pfizer Inc.'s ( NYSE:PFE ) request for a temporary restraining order to prevent Metsera, Inc. ( NASDAQ:MTSR ) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S ( NYSE:NVO ) .

https://www.benzinga.com/m-a/25/11/48693778/pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal

Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles

NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.

https://www.zacks.com/stock/news/2785838/novo-nordisk-q3-earnings-revenues-miss-glp-1-drugs-face-us-hurdles

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs - Novo Nordisk ( NYSE:NVO )

Novo Nordisk A/S ( NYSE:NVO ) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion ( 74.98 billion Danish kroner ) , slightly below the consensus of $11.88 billion. Sales increased by 5% in Danish kroner and 11% at constant currency.

https://www.benzinga.com/markets/earnings/25/11/48649600/ozempic-maker-novo-nordisk-trims-growth-outlook-for-obesity-drugs

Trending Today

Solana ($SOL) Crypto Forecast: Down 5.5% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Down 5.4% Today

Evergy Inc. ($EVRG) Stock Forecast: Down 1.9% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.5% Today

Novo Nordisk A/S ($NVO) Stock Forecast: Down 5.2% Today

Chegg Inc. ($CHGG) Stock Forecast: Up 12.1% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Down 21.9% Today

CarMax Inc ($KMX) Stock Forecast: Down 25.1% Today

Reddit Inc ($RDDT) Stock Forecast: Down 6.1% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Down 5.1% Today

Novo Nordisk A/S Price History

26.07.2025 - NVO Stock was down 5.0%

• Reports of at least 20 deviations linked to hair contamination and lack of thorough investigations may have raised concerns about product quality and safety standards, leading to a loss of investor confidence.
• The filing of multiple securities fraud class action lawsuits against Novo Nordisk could have created uncertainty and negative sentiment around the stock, impacting its price negatively.
• The revelation of a purchase of Novo Nordisk stock by Rep. Marjorie Taylor Greene might not have been enough to offset the overall bearish sentiment surrounding the company due to the other negative developments.

30.09.2025 - NVO Stock was down 5.3%

• Novo Nordisk saw a decrease in its stock price, closing at $52.05, reflecting a -1.59% change from the previous day.
• Investors raised concerns following the company's proposal to acquire Metsera, Inc., impacting sentiment on Novo Nordisk's financials and strategic outlook.
• Eli Lilly's strong market performance in GLP-1s, a key competitive area with Novo Nordisk, may have added to the pessimism surrounding Novo Nordisk's stock.
• The stock's decline could also be attributed to broader market trends, with investors potentially adjusting their portfolios in response to the overall market uptick.

08.07.2025 - NVO Stock was up 5.2%

• The bullish movement in NVO stock could be attributed to the company's strong Q2 earnings beat despite revenue missing estimates, showcasing resilience in challenging market conditions.
• The increase in sales by 16% in Danish kroner and 18% at constant exchange rates reflects positive growth momentum for Novo Nordisk, boosting investor confidence.
• Despite facing US hurdles and competition for its GLP-1 drugs, the company's overall performance and revenue growth seem to have outweighed these challenges, leading to the bullish market movement.
• The trading activity by board members and executives might have also signaled confidence in the company's future prospects, further contributing to the positive sentiment surrounding NVO stock.

05.10.2025 - NVO Stock was down 5.4%

• Lower-than-anticipated sales figures in the third quarter of 2025 resulted in a decline in Novo Nordisk's stock value.
• Investor apprehension arose following the company's revised growth projections for obesity drugs, prompting concerns about its future revenue in this cutthroat market.
• The escalating competition with Pfizer for the purchase of weight-loss drug manufacturer Metsera Inc. has injected uncertainty and downward pressure on Novo Nordisk's stock, as investors navigate the implications of the heightened bid and the shifting dynamics of the weight loss and diabetes medication segment.
• Amid Novo Nordisk's robust sales expansion in the initial three quarters of 2025 and ongoing advancements in its research and development pipeline, market sentiment appears predominantly influenced by immediate worries surrounding its obesity drug division and the unfolding acquisition saga with Pfizer.

04.10.2025 - NVO Stock was up 2.4%

• Novo Nordisk experienced strong bullish movement following the submission of an updated proposal to acquire Metsera, Inc., which has been considered superior to Pfizer's offer. This reflects market confidence in Novo Nordisk's strategic positioning in the weight-loss drug sector.
• Lawsuits filed by Pfizer to impede Novo Nordisk's bid may have introduced some uncertainty to the market, but investors appear optimistic about Novo Nordisk's potential in the acquisition.
• The impending Q3 earnings report for Novo Nordisk is a key aspect to monitor, considering the company's performance against challenges like slowing momentum for key drugs such as Wegovy and Ozempic, pricing risks, and intense market competition.
• Antitrust accusations by Pfizer against Novo Nordisk in the Metsera takeover battle could lead to stock volatility; however, the current bullish trend suggests investors are prioritizing the potential benefits of the acquisition for Novo Nordisk.

18.08.2025 - NVO Stock was up 5.9%

• Novo Nordisk's stock surged today due to positive results from its weight-loss pill, Wegovy, which demonstrated a significant reduction in cardiovascular event risk compared to a competitor's treatment.
• The company's next-generation obesity treatment candidate, cagrilintide, also showed promising results in a phase III study, further boosting investor confidence.
• Analyst sentiment and upgrade momentum for Novo Nordisk increased, fueled by the successful clinical outcomes and the potential growth narrative reset in the weight-loss market.
• Despite facing FDA scrutiny alongside other companies in the weight-loss treatment sector, Novo Nordisk's strong performance and positive data overshadowed any regulatory concerns, leading to a bullish market movement.

17.09.2025 - NVO Stock was down 5.2%

• NVO stock closed lower at $56.09, down by -1.11% from the previous day's close.
• President Trump's comments on weight-loss drugs potentially lowering in price may have negatively impacted NVO and Eli Lilly's stock prices.
• The increase in Novo Nordisk's short interest could have added selling pressure on the stock, contributing to the bearish movement.
• The $2.1 billion deal between NVO and Omeros to bolster their rare disease portfolio might not have been well received by investors, possibly due to concerns about the impact on NVO's financials or strategic direction.

17.09.2025 - NVO Stock was down 5.2%

• NVO's stock price decreased by 1.11% after remarks from a prominent government official about reducing drug prices, with particular emphasis on weight-loss medications.
• The rise in Novo Nordisk's short interest is believed to have played a role in the downward movement, as some investors seem to be anticipating a further drop in the stock price.
• Despite finalizing a significant deal worth $2.1 billion to enhance its rare disease portfolio, concerns about weight-loss drugs and potential pricing restrictions took precedence in the market, resulting in the decline in NVO's stock.

06.10.2025 - NVO Stock was down 5.2%

• Disappointing Q3 earnings and revenues for Novo Nordisk were driven by the slower growth of its obesity drugs, Wegovy and Ozempic, particularly in the U.S.
• Despite efforts to reduce drug prices and improve patient access, challenges in the pharmaceutical industry may have led to a negative market response.
• Competition, exemplified by Pfizer's unsuccessful attempt to block Novo Nordisk's acquisition of Metsera, likely impacted Novo Nordisk's stock price.
• Novo Nordisk revising its growth forecast for obesity drugs may have raised concerns about future profitability and market performance.

06.10.2025 - NVO Stock was up 4.3%

• Novo Nordisk's higher-dose trial results for Wegovy showcasing weight loss and cardiovascular benefits likely boosted investor confidence in the company's obesity drug portfolio.
• The denial of Pfizer's attempt to block Novo Nordisk's bid for Metsera may have signaled to investors the company's commitment to expanding its offerings and market presence.
• Despite Q3 earnings missing expectations and a trimmed growth outlook for obesity drugs, Novo Nordisk's overall sales growth and progress in its R&D pipeline seem to have reassured investors about the company's long-term prospects.
• The market's positive reaction to Novo Nordisk's announcements today suggests that investors are focusing more on the company's future potential and pipeline progress rather than short-term financial performance.

01.09.2025 - NVO Stock was up 5.2%

• Novo Nordisk's upward movement could be attributed to its expansion beyond current obesity treatments like Wegovy and Ozempic with next-generation candidates, signaling potential for market leadership in the obesity sector.
• The announcement of a class action lawsuit by the Portnoy Law Firm on behalf of NVO investors during a specific period may have initially caused some uncertainty, but the market appears to have reacted positively to other growth prospects.
• Despite fluctuations in related stocks such as Inventiva and Electronic Arts, Novo Nordisk stood out with its positive momentum, demonstrating resilience amid wider market changes.
• Investor confidence in Novo Nordisk may have been bolstered by the limited impact of the lawsuit, leading to increased buying interest and driving the stock price up.

18.08.2025 - NVO Stock was up 5.2%

• The bullish movement in NVO stock can be attributed to the promising Phase III data for its next-generation obesity treatment candidate, cagrilintide, which showed significant weight loss in a clinical study.
• Additionally, the real-world study demonstrating Wegovy's superior cardiovascular risk reduction compared to tirzepatide could have further boosted investor confidence in Novo Nordisk's innovative treatments.
• The potential FDA approval for a high-dose version of Wegovy also signals growth opportunities for Novo Nordisk in the weight-loss market, attracting more investors to the stock.
• Despite recent challenges and a significant decline in stock value, the positive developments in Novo Nordisk's product pipeline seem to have reignited investor optimism and sparked today's bullish momentum.